Dinko Valerio is a prominent figure in the biopharmaceutical sector with extensive experience in leadership and innovation. As Co-founder and Executive Chairman of Leyden Labs since 2020, and Co-founder and Chairman of the Board at ProQR Therapeutics since 2012, Valerio has played a significant role in advancing gene therapy and vaccine development. Valerio co-founded AESCAP Venture and served as Managing Partner from 2006 to 2016, while also founding and leading Crucell, a Dutch biopharmaceutical company specializing in vaccines, from 1993 until its acquisition by Johnson & Johnson in 2004. Additionally, Valerio held academic positions, including Professor of Gene Therapy at Leiden University Medical Center and Group Leader of Gene Therapy at TNO Radiobiological Institute. Valerio's academic background includes a PhD, cum laude, from Leiden University.